Juan Polanco
Medical · Fairlawn, VANPI 1992117311
Payments from drug & device makers
Across 94 payments — averaging $19.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$253
- AbbVie$212
- Novo Nordisk$180
- Pfizer$162
- AstraZeneca$161
- Exact Sciences$152
- plus $697 from 16 others
What the payments were for
- Food & beverage$1,817100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 13 | $253 |
| AbbVie | 10 | $212 |
| Novo Nordisk | 10 | $180 |
| Pfizer | 9 | $162 |
| AstraZeneca | 10 | $161 |
| Exact Sciences | 7 | $152 |
| Amgen | 10 | $150 |
| Neurocrine Biosciences, Inc. | 6 | $140 |
| Orthofix Medical, Inc. | 1 | $85 |
| GSK | 3 | $52 |
| Idorsia Pharmaceuticals US Inc | 2 | $33 |
| Astellas Pharma US Inc | 2 | $31 |
| Teva Pharmaceuticals USA, Inc. | 2 | $30 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $27 |
| Gilead | 1 | $25 |
| Johnson & Johnson | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Eisai Inc. | 1 | $19 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Xeris Pharmaceuticals, Inc. | 1 | $16 |
| Boehringer Ingelheim | 1 | $15 |
| Bayer | 1 | $14 |
How this compares
$1,817 in reported general payments places this provider in the 70th percentile of 632 medical providers in Virginia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 15 | $21,239 |
| TrulicityDulaglutide | 22 | $21,109 |
| EliquisApixaban | 23 | $15,938 |
| FarxigaDapagliflozin Propanediol | 22 | $14,991 |
| OzempicSemaglutide | 11 | $10,391 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $4,333 |
| Buprenorphine | 11 | $3,524 |
| Solifenacin Succinate | 17 | $2,254 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 128 | $2,126 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 77 | $1,983 |
| Levothyroxine Sodium | 77 | $1,153 |
| Celecoxib | 37 | $989 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 11 | $874 |
| Sucralfate | 13 | $820 |
| Famotidine | 75 | $746 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $212 | $21,23915 claims |
| Lilly USA, LLCTrulicity | $253 | $21,10922 claims |
| AstraZenecaFarxiga, Symbicort | $161 | $19,32333 claims |
| PfizerEliquis | $162 | $15,93823 claims |
| Novo NordiskOzempic | $180 | $10,39111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 632 medical providers in Virginia.
Other medical in Fairlawn
- Bryan UrquhartFredericksburg$264K
- Sara VillalonaRichmond$240K
- Sarah SafaLansdowne$171K
- Waseem GarbiaFairfax$114K
- Rana HassanAshburn$54K
- Brian LamFalls Church$51K
- Christine KesslerKing George$20K
- Janlyn AnthonyRichmond$18K
- Cara DepanfilisNorfolk$17K
- Nicholas DeptulaRichmond$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.